Secondary endpoints included the composite of cardiovascular mortality purchase genuine propecia on-line hair loss cure science, non-fatal MI buy propecia 5 mg otc hair loss in men, or nonfatal stroke, and the composite of these outcomes plus coronary revascularization, carotid endarterectomy/carotid stenting, hospitalization for unstable angina, or hospitalization for heart failure. There were few events reported, and no cardiovascular deaths. There were 2 instances of the first composite endpoint in the glimepiride group and none in the pioglitazone group. On the second composite endpoint, there were 10 events in the glimepiride group (8 ofwhich were coronary revascularization) and 4 in the pioglitazone group (3 coronary revascularization). PERISCOPE was another trial of pioglitazone compared to glimepiride designed to 154 measure progression of atherosclerosis in patients with type 2 diabetes. After 18 months of follow-up, there was no difference between groups in the occurrence of clinical endpoints, including the composite of cardiovascular death, nonfatal MI, or nonfatal stroke (2. There were 3 cardiovascular deaths in the pioglitazone group and 1 in the glimepiride group (P=0. In a small, fair-quality, randomized controlled trial (N=47), patients with impaired glucose tolerance or type 2 diabetes (combined in the analysis) in addition to nonalcoholic steatohepatitis, received either pioglitazone 45 mg daily or placebo, in addition to a weight loss 82 intervention. Glycemic control improved with pioglitazone compared with placebo (P<0. Plasma aspartate and alanine aminotransferase levels and hepatic fat content all decreased with treatment compared with placebo (P<0. Histologic changes in the liver also improved significantly with pioglitazone. Thiazolidinediones Page 54 of 193 Final Report Update 1 Drug Effectiveness Review Project 93 In another small trial, patients with acute coronary syndrome received pioglitazone or no additional treatment starting 2 weeks after percutaneous, bare metal stent placement. At 6- months follow-up these researchers demonstrated that late luminal loss was less in the pioglitazone group than in the control group (P=0. Major cardiac events (myocardial infarction or revascularization of the target lesion) were significantly decreased in the pioglitazone group at 6 months compared with the control group (7. Takagi and colleagues compared pioglitazone with placebo in 44 patients with type 2 78 diabetes who had undergone coronary stent implantation. After 6 months of follow-up, angiographic in-stent restenosis (19% compared with 46%; P=0. There was no difference in A1c levels at follow-up in this study (See Key Question 1). The updated search identified several important recent trials of rosiglitazone reporting 148 57 vascular or mortality outcomes: the RECORD trial and ADOPT. An interim analysis of the 148 RECORD trial was published by Home and colleagues in 2007. In this open-label, multicenter, noninferiority, randomized controlled trial (N=4458), subjects who were already taking a sulfonylurea were randomized to add-on rosiglitazone 4 mg daily (titrated up to 8 mg daily) or metformin (titrated up to 2550 mg daily). Subjects taking metformin at study entry were randomized to add-on sulfonylurea (glyburide, gliclazide or glimepiride, depending on physician preference). The primary outcome for the RECORD study was hospitalization for any of the following: acute myocardial infarction, congestive heart failure, stroke, unstable angina pectoris, transient ischemic attack, unplanned cardiovascular revascularization, amputation of an extremity for any other definite cardiovascular reason, or death from cardiovascular causes. For the adjudicated primary endpoint of hospitalization or death from cardiovascular disease, the hazard ratio for rosiglitazone (plus metformin or a sulfonylurea) compared with metformin plus a sulfonylurea was 1. The time-to-event curves suggested divergence of treatment effects after 2. There were no significant differences between rosiglitazone and the control groups for secondary endpoints of acute myocardial infarction, death, or a composite of cardiovascular death, myocardial infarction, and stroke. The elevated hazard ratio for the primary endpoint was mainly driven by the increase in congestive heart failure in the rosiglitazone group compared with the control group (hazard ratio for adjudicated events 2. The RECORD study underwent the interim analysis discussed herein due to concerns raised about the safety of rosiglitazone and its potential for causing congestive heart failure and 63 cardiac events. Because this was an interim analysis, the study was not powered to detect differences in cardiovascular end points in this follow-up period. Thus interpretation of this interim analysis must be done with great caution. Subjects with significant renal or hepatic disease, unstable or severe angina, or congestive heart failure of any New York Heart Association class were excluded. Approximately half of subjects Thiazolidinediones Page 55 of 193 Final Report Update 1 Drug Effectiveness Review Project 155 had hypertension, 81% had metabolic syndrome, and 45% were smokers. The number of deaths from all causes was similar across the 3 groups, but more cardiovascular events were reported in the rosiglitazone group (4. Congestive heart failure events were higher with rosiglitazone than with glyburide (further details are presented in Key Question 8). The lower rates of cardiovascular events in the glyburide group were primarily due to lower rates of nonfatal myocardial infarction and congestive heart failure in this group. Several additional, smaller rosiglitazone trials were also identified in the updated 108, 110 search. In a very small (N=16), poor-quality, randomized controlled trial, subjects with coronary stent implantation were randomized to rosiglitazone 4-8 mg daily or placebo for 6 months. Rosiglitazone did not reduce in-stent restenosis and there were no differences in cardiac 108 events between the groups. For patients with prediabetes or metabolic syndrome, do thiazolidinediones differ from one another or from placebo in improving weight control a. Summary of the Evidence • It is not possible to conclude whether there is a difference in weight change between pioglitazone and rosiglitazone. Detailed Assessment Updated report: This question was not included for the updated report. The effects of pioglitazone and rosiglitazone on weight are reviewed in the section addressing adverse events. There is a paucity of data on the comparative effect of pioglitazone and rosiglitazone and the effect of these drugs compared with placebo on weight or abdominal obesity. It is not possible to conclude whether there is a difference in weight change with 1 of the thiazolidinediones. Weight or body mass index was measured in 6 studies of prediabetes or the metabolic 66 syndrome (Table 13), including 2 head-to-head studies. One head-to-head study reported increased weight with both pioglitazone and rosiglitazone with no significant difference between 156 groups; the other study reported weight gain with pioglitazone (2. Pioglitazone, either alone or in combination with metformin or a sulfonylurea was associated with an increase in weight compared with metformin or a sulfonylurea as 157 monotherapy. Rosiglitazone did not produce a significant change in weight compared with Thiazolidinediones Page 56 of 193 Final Report Update 1 Drug Effectiveness Review Project 158 159 159 placebo in 1 small study and in an additional poor-quality study. Waist-to-hip ratio and 158 waist circumference also did not change with rosiglitazone compared to placebo.
Because the authors did not conduct a statistical analysis of the difference in adverse events between solifenacin and tolterodine order propecia without prescription hair loss cure two years, we did a statistical analysis of the adverse event rates of the STAR trial ourselves using the StatsDirect program cheap propecia 5mg overnight delivery hair loss zones. The investigators did a post hoc analysis of the STAR trial data to determine which drug most quickly led to 106 improvement. The analysis compared tolterodine with the initial dose of solifenacin (tolterodine extended-release 4 mg compared with solifenacin 5 mg over the first 4 weeks of the trial). Overactive bladder Page 25 of 73 Final Report Update 4 Drug Effectiveness Review Project In the final included study, darifenacin (15 mg and 30 mg doses) was compared with 105 immediate-release oxybutynin in a crossover study with 2 weeks in each treatment arm. Episodes of incontinence and frequency of micturition Short-acting compared with long-acting drugs 22, 47 Two fair-quality studies that titrated extended-release or immediate-release oxybutynin to adverse events or efficacy reported no significant difference between groups in the mean change in number of incontinence episodes per week. Converted to mean change in incontinence episodes per day, the mean change in the extended-release groups was -3. Time period from baseline to assessment was not reported. Alza, the manufacturer of the extended-release formulation, funded both studies. A study comparing extended-release oxybutynin (10 mg once daily) with immediate- 25 release oxybutynin (5 mg twice daily) used an extended-release formulation that is not available in the United States. It also used different outcome measures than the other studies: proportion of patients with daytime and nighttime continence, day/night micturition, and day/night incontinence. For these reasons, we did not evaluate this study any further. An additional study comparing titrated “optimal” doses of 10 to 30 mg oxybutynin extended-release once daily (increasing in 5 mg increments) or 5 mg oxybutynin immediate- release twice daily (also maximum of 30 daily) showed that the mean titrated doses were similar, with 15. Baseline reductions in incontinence episodes per 24 hours were 2. Similarly, reductions in micturitions per 24 hours at the end of treatment were 1. These differences were not statistically significant. This was a study of an extended-release product introduced into the Canadian market by Purdue Pharma and is currently not available in the United States. The OPERA study compared extended-release tolterodine 4 mg once daily with 46 immediate-release tolterodine 2 mg twice daily and found no significant difference in mean change (absolute) in frequency of micturition or episodes of incontinence over one week. Converted to per day, the mean change in frequency of micturition was –3. Mean change in the number of urinary pads used per day was –3. The median percent change in incontinence episodes was also reported. The percent reduction was 71% for extended-release, 60% for immediate-release, and 33% for placebo. The authors stated that they used the median rather than the mean, and the percent reduction, because the data were positively skewed and they believed the relative change was more relevant than the absolute change. Because few other studies report data in this way, the comparability of these results to other trials is somewhat limited. Overall withdrawal was 12%, with similar rates in the 2 drug treatment groups. In a post hoc analysis of the OPERA trial, women who were anticholinergic drug naïve, efficacy and tolerability outcomes were not different between the drugs, with the exception that oxybutynin extended- 107 release was associated with a lower frequency of micturition (P=0. The post hoc analysis did however find differences among the women with anticholinergic experience. Extended- release oxybutynin was associated with significantly reduced micturition frequency compared Overactive bladder Page 26 of 73 Final Report Update 4 Drug Effectiveness Review Project with extended-release tolterodine (P=0. Significantly more women reported no urge incontinence at study endpoint in the oxybutynin extended-release group compared with the tolterodine extended-release group (23. Extended-release oxybutynin was compared with immediate-release tolterodine in 1 23 study. On the basis of an analysis of covariance, with adjustment for baseline and severity of symptoms, oxybutynin extended-release was significantly more effective at reducing the number of incontinence episodes per week (P=0. This analysis was not intention-to-treat; the proportions of patients excluded from the analysis were 14% in the oxybutynin extended-release group and 11% in the tolterodine group. Therefore, due to dropouts, the analysis may not reflect actual reductions in efficacy. Insufficient data were presented for us to calculate the mean change in incontinence or micturitions based on intention-to-treat. Extended-release tolterodine was compared with immediate-release oxybutynin in Japan 36 and Korea. No significant differences were found in percent change in median number of incontinence episodes, pad use, or frequency of micturition. The median percent change in incontinence episodes was 78. The absolute change was not reported and again the data were reported to be skewed. A study of solifenacin 5 mg or 10 mg once daily and immediate-release tolterodine 2 mg twice daily demonstrated that both doses of solifenacin and tolterodine produced significantly 50 lower mean frequency of micturition than placebo. Solifenacin at both doses, but not tolterodine, resulted in statistically significant improvements in urge and number of incontinence episodes per 24 hours and episodes of urgency. Only solifenacin 10 mg was better than tolterodine for reducing frequency of micturition. Patients administered solifenacin had significantly decreased urgency, incontinence, urge 28 incontinence, and pad usage. However, the study did not demonstrate statistically significant between-treatment differences in the primary endpoint, frequency of micturition, or in nocturia episodes, thus solifenacin was non-inferior to extended-release tolterodine for these measures. Data for both doses of solifenacin were combined for analysis of outcomes. A post hoc analysis of only solifenacin 5 mg and extended-release tolterodine 4 mg in the initial 4 weeks of the STAR trial showed a significantly greater mean reduction in number of 106 incontinence episodes per 24 hours for solifenacin (–1. A head-to-head trial used a crossover design to compare darifenacin (15 mg or 30 mg once daily) with immediate-release oxybutynin (5 mg 3 times daily). Darifenacin (both doses) and oxybutynin were significantly better than placebo for reducing the number of incontinence episodes per day and reducing the frequency of micturition, but no significant difference in 105 efficacy was found between the drugs. Symptoms and overall assessment of benefit Short-acting compared with long-acting drugs One study comparing immediate-release oxybutynin with extended-release tolterodine in 36 Japanese and Korean women assessed subjective outcome measures. Patients were asked to Overactive bladder Page 27 of 73 Final Report Update 4 Drug Effectiveness Review Project assess their perception of bladder condition (on a 6-point scale), urinary urgency (on a 3-point scale), overall treatment benefit (on a 3-point scale), and quality of life (measured by the King’s Health Questionnaire) at baseline and 12 weeks.
IGH translocations induce up-regulation of different oncogenes order propecia 1 mg on line hair loss 6 months after giving birth, it is Learning Objectives possible that all IGH translocations involved in MM converge on a ● To understand that myeloma should no longer be considered common pathway that is essential in the pathogenesis of the disease as a single entity and cause the inhibition of differentiation and an increase in cell ● To understand that better tools for diagnosis and monitoring survival and proliferation order 5 mg propecia with visa hair loss in men quilters. Gene expression proﬁling (GEP) analysis treatment efﬁcacy are being implemented has demonstrated that expression of the cyclin proteins (CCND1, ● To understand that the treatment goal is to ﬁnd the best CCND2, and CCND3) is increased in almost all MM patients, possible balance among efﬁcacy, toxicity, and cost supporting the hypothesis that there is a potential unifying event in its pathogenesis. The nonhyperdiploid patients Multiple myeloma (MM) is the second most common hematological are characterized by a very high prevalence of IGH translocations, malignancy, with an annual incidence of 4 new cases per 100 000 monosomy/deletion 13, and gains on 1q. It accounts for 1% of all malignant diseases and 15% of all loid group is associated with recurrent trisomies involving odd hematological malignancies. In the pathogenesis of MM, the chromosomes (3, 5, 7, 9, 11, 15, and 19) and with a low incidence of mechanisms responsible for the interaction between malignant structural chromosomal abnormalities. Deletion of tumor cell growth, survival, and migration; and drug resistance. The chromosome 17p deletion, which includes loss of Genome instability is a prominent feature of myeloma cells and, in TP53, occurs at a lower frequency in newly diagnosed MM fact, almost all patients with MM are cytogenetically abnormal. Furthermore, 17p deletion is associated with extramed- involving the IGH locus on chromosome 14q32, copy number ullary MM. Approximately 40% of MM tumors have IGH translocations to be late oncogenic events and are associated with disease involving 5 recurrent chromosomal patterns: 11q13 (CCND1), 4p16 progression. Most karyotypic abnormalities involving MYC corre- (FGFR/MMSET), 16q23 (MAF), 6p21 (CCND3), and 20q11 spond to complex translocations and insertions that are often (MAFB), corresponding to an incidence of 15%-20%, 15%, nonreciprocal and frequently involve 3 different chromosomes. Is this dictated only by the genotypic frequently associated with disease progression. Until recently, the pathogenic models assumed that MM New insights into MM genetics develops through a multistep transformation from normal PCs to GEP analysis has conﬁrmed the huge genetic diversity of MM MGUS (implying PC immortalization) and subsequent transforma- cases, and several genomic classiﬁcation models have been pro- tion into active MM, in which clonal PCs are responsible for posed by the Arkansas, French, and Dutch groups. However, studies based on FISH, single- accepted is the Arkansas TC model, which connects genetic nucleotide polymorphism arrays, and whole-genome sequencing abnormalities, cell transcriptome, and clinical features of patients have demonstrated that most genetic lesions typically observed in and classiﬁes MM patients into 7 different groups. Each group MM are already present in MGUS patients and that the progression displays a speciﬁc genetic signature, some of which are associated from MGUS to SMM, and eventually to MM, would involve a with a particular IGH translocation or ploidy status and with a 6 clonal expansion of genetically abnormal PCs, implying a complex characteristic clinical behavior. However, so far, the reproducibil- 10 evolutionary process with intraclonal heterogeneity. Three distinct ity of these GEP models has not been optimal and they have not 6 patterns of genomic evolution have been proposed based on data been implemented in the clinical milieu except in selected centers. Interestingly, mutations were often present 2,11 barely present at diagnosis. Patients with high-risk cytogenetics in subclonal populations and multiple mutations within the same 1 usually follow the last 2 evolutionary models. These ﬁndings are pathway (eg, RAS and BRAF) were observed in the same patient. For example, even though patients leukemia and Waldenstrom’s macroglobulinemia, which feature the harboring the BRAF mutation might respond to BRAF inhibitors, single unifying mutations BRAF and MYD88, respectively. Therefore, mutations are often present in there is limited evidence of its role in the pathogenesis of MM. CDKN2A, SOCS, and TGFBR2), overexpression of the histone methyltransferase MMSET, and the presence of mutations of UTX Mechanism of resistance (histone demethylase) have been described. Furthermore, genome- The ﬁnal step in this continuous transformation process from wide methylation studies have shown both global DNA hypometh- MGUS into symptomatic MM is illustrated by those MM patients ylation and gene-speciﬁc DNA hypermethylation in MM, with who are refractory to treatment. Two major types of chemoresis- certain epigenetic signatures being associated with prognostic 7 tance have been identiﬁed: intrinsic and acquired. Another area of emerging interest in cancer tance has mainly been associated with gene deregulation driven by pathogenesis concerns miRNAs, small, noncoding RNAs that speciﬁc genetic abnormalities such as the t(4;14), t(14;16), del(17p), regulate gene expression at the posttranscriptional level and are 2 and TP53 abnormalities. Nevertheless, we still lack a complete involved in critical biological processes including cellular growth understanding of the precise mechanisms responsible for drug and differentiation. Various studies have shown that miRNA resistance driven by these genetic hits. Moreover, patients without expression is deregulated in myeloma cells compared with normal these abnormalities also show primary resistance to therapy, plasma cells and that their GEP proﬁle is associated with genetic 8 indicating that other alterations are also involved. Moreover, several miRNAs are known to be in- seminal work identifying cereblon (CRBN) as the binding protein of volved in MM pathogenesis. Indeed, a mechanism has been immunomodulatory drugs (IMiDs) [which, in PCs, leads to the identiﬁed by which miRNAs act on MDM2 expression to regulate ubiquitination of substrates such as Ikaros (IKZF1) and Aiolos p53; therefore, miR-192, miR-194, and miR-215 reexpression in (IKZFe)], more recent studies have already shown that CRBN and myeloma cell lines induces degradation of MDM2, with subsequent 9 IKZF1 levels correlate with survival in MM patients treated with up-regulation of p53 and inhibition of cell growth. To fully describe this intrin- sic resistance, we need to consider the contribution of the interaction Multistep pathogenesis and drug resistance of malignant PCs with the BM microenvironment, which provides a MM is a unique cancer paradigm for investigating the mechanisms sanctuary for myeloma cells by promoting proliferation and block- involved in the emergence of a premalignant condition and its ing apoptosis, thereby enabling tumor progression and the eventual transition to a malignant disease; in other words, from an “early/ emergence of drug resistance. The second type of resistance, acquired resistance, is easily ultimately resistant/refractory MM). Unfortunately, the key ques- recognized in the clinical setting when patients’ tumor cells become tions in this process are yet to be answered: why does a quiescent refractory to the treatment strategies used. We can consider 2 2 American Society of Hematology Table 1. Factors prognostic of high-risk disease signiﬁcance of cytogenetic abnormalities at relapse is not so well established. Finally, the recently reported positive results for Patient-speciﬁc factors Age tandem autologous stem cell transplantation (ASCT), particularly in patients with t(4;14), should be highlighted. However, the deﬁnition of complete 2 Circulating plasma cells response (CR) is far from optimal and more sensitive techniques for Extramedullary disease evaluating MRD both outside the BM (eg, imaging techniques such Tumor resistance (failure to respond) as MRI or PET) and inside the BM [eg, immunophenotyping by multiparametric ﬂow cytometry (MFC) or molecular analysis by * Cardiacfailure,renalfailure. The Italian and Arkansas groups have shown that failure (OS: 2 y). Ultra-high risk can also be deﬁned by the coexistence of adverse to achieve complete ﬂudeoxyglucose-PET suppression after trans- cytogenetics, ISS III, and either high lactate dehydrogenase (LDH) or failure to plantation is associated with shorter survival. Spanish and UK groups have both shown that, in transplanted and elderly MM patients, persistence of MRD is associated with putative mechanisms by which acquired or secondary resistance signiﬁcantly poorer outcome and this parameter is of signiﬁcantly more prognostic power than negative immunoﬁxation14,20; however, arises: self-altered genomic/transcriptomic cell machinery in re- sponse to chemotherapy and the presence of substantial clonal further standardization of MFC is still required. Allele-speciﬁc heterogeneity within the initial MM tumor clone. The latter oligonucleotide-PCR also predicts outcome and is probably one log mechanism requires several clones to coexist and compete with one more sensitive than MFC, but is signiﬁcantly less applicable (50% another within the myelomatous population in such a way that vs 95%). Preliminary data from next-generation sequencing indicate treatment eradicates the major clone (chemosensitive) and a minor, high applicability and sensitivity (90%), making the technique a possible alternative to MFC. Our group has patchy pattern of myeloma BM inﬁltration, a negative MRD result shown that even in patients who achieve complete hematological may not be indicative of disease eradication, but rather the result of remission, a small chemoresistant clone [minimal residual disease a nonrepresentative BM sample. The MRD clone may be a unique model, the of high-dose melphalan followed by stem cell support (ASCT) for analysis of which can help us to understand chemoresistance and the young myeloma patients, whereas for elderly patients, MP remained characteristics of eventual MM clonogenic cells and ultimately to the standard treatment. In contrast, since 2000, a revolution in the design therapeutic strategies to overcome resistance. The understand- treatment of MM has been made possible by the availability of new ing of the molecular, biological, and functional characteristics of agents with distinct mechanisms of action: the IMiDs thalidomide and these MRD cells, along with the investigation of whether these cells lenalidomide and the proteasome inhibitor bortezomib. Currently, only myeloma patients with symptomatic disease (de- Prognostic factors and tools for monitoring treatment ﬁned by CRAB criteria) are recommended for treatment. The Spanish group has conducted a phase 3 randomized paid to performance status (frailty) and comorbidities because they trial on high-risk SMM comparing early treatment with lenalidomide– clearly affect treatment options and cause a risk of toxicity, drug dexamethasone versus observation. The results showed that the discontinuation, and shorter survival. Cytogenetic/FISH evaluation experimental arm is associated with a signiﬁcant delay in progres- on puriﬁed PCs is essential in all patients with newly diagnosed MM sion to symptomatic myeloma [3-year progression-free survival because of its impact on disease outcome.
Ferguson AC cheap 5mg propecia fast delivery hair loss concealer, Spier S purchase generic propecia on line hair loss cure 2015 histogen, Manjra A, Versteegh FG, Mark S, Zhang P. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. The effect of high-dose fluticasone propionate and budesonide on lung function and asthma exacerbations in patients with severe asthma. Hoekx JC, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 microg x day(-1). A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: A clinical evaluation. Controller medications for asthma 191 of 369 Final Update 1 Report Drug Effectiveness Review Project 48. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Weiss KB, Liljas B, Schoenwetter W, Schatz M, Luce BR. Effectiveness of budesonide administered via dry-powder inhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler for adults with persistent asthma in managed care settings. Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. Differential effects of inhaled corticosteroids: Fluticasone propionate versus triamcinolone acetonide. Hydrofluoroalkane-beclomethasone dipropionate effectively improves airway eosinophilic inflammation including the distal airways of patients with mild to moderate persistent asthma as compared with fluticasone propionate in a randomized open double-cross study. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Vermeulen JH, Gyurkovits K, Rauer H, Engelstatter R. Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Controller medications for asthma 192 of 369 Final Update 1 Report Drug Effectiveness Review Project 62. Comparison of the efficacy and safety of ciclesonide 160 microg once daily vs. Bateman ED, Linnhof AE, Homik L, Freudensprung U, Smau L, Engelstatter R. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Boulet LP, Bateman ED, Voves R, Muller T, Wolf S, Engelstatter R. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Comparison of a step-down dose of once-daily ciclesonide with a continued dose of twice-daily fluticasone propionate in maintaining control of asthma. Magnussen H, Hofman J, Staneta P, Lawo JP, Hellwig M, Engelstatter R. Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pedersen S, Garcia Garcia ML, Manjra A, Theron I, Engelstatter R. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. A 24-week comparison of low-dose ciclesonide and fluticasone propionate in mild to moderate asthma. Wardlaw A, Larivee P, Eller J, Cockcroft DW, Ghaly L, Harris AG. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Effect of the two different leukotriene receptor antagonists, montelukast and zafirlukast, on quality of life: a 12- week randomized study. Campbell LM, Anderson TJ, Parashchak MR, Burke CM, Watson SA, Turbitt ML. A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Controller medications for asthma 193 of 369 Final Update 1 Report Drug Effectiveness Review Project 77. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.